Our index tracks 6 of the largest clinical-stage startups, which have an average market capitalization of $65.5M and an average stock price of $0.69/share.

The 10 companies in our Psychedelic Compounds-Based Drug Stocks Index are clinical-stage startups still in the product research and development of novel compounds with no products and no revenue.

Updating the stock performances of the 13 constituents in our Pure-Play Marijuana and Psychedelic Compounds-Based Drug Stocks Index: up last week but still down 32% YTD.

Our index of the 13 companies working on drugs based on marijuana and/or psychedelics declined -6% last week and is now -37% YTD.

Thirteen clinical-stage companies with the largest market capitalizations are tracked in our Pure-Play Marijuana (4) and Psychedelic Compounds-Based (9) Drug Stocks Indexes.